Chronotherapeutic dosage forms and methods of treatment using chronotherapy

a technology of chronotherapy and dosage forms, applied in the direction of drug compositions, pharmaceutical product forms, inorganic non-active ingredients, etc., can solve the problems of inability to achieve the effect of reducing the incidence of early morning cardiovascular events, and improving the effect of blood pressure control

Inactive Publication Date: 2003-05-01
PENWEST PHARMA CO
View PDF3 Cites 113 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Benefits of technology

0163] Chronotherapy is a treatment approach that allows for better control of blood pressure during the day and night by delivering medication in amounts proportional to patients' needs and, therefore, in synchrony with the circadian blood pressure rhythm. More chronotherapeutic antihypertension medication is delivered in the morning and daytime when blood pressure is greatest, and less at night when blood pressure typically declines to the lowest level. The incidence of early morning cardiovascular events could theoretically be decreased if early morning surges in blood pressure and heart rate are blunted by the chronotherapeutic administration of indicated drugs using appropriate delivery systems.
0164] The calcium channel blocker verapamil reduces heart rate as well as blood pressure, which is especially beneficial for patients with both ischemic heart disease and hypertension. These characteristics of verapamil and its appropriate half-life made it a good choice for the formulation of an antihypertensive drug with a chronotherapeutic oral drug absorption system (CODAS). This system was designed to be taken at bedtime, to cause a 4- to 5-hour initial lag in drug delivery and, thereafter, to achieve a controlled release of drug. CODAS-verapamil capsules (Verelan.RTM. PM) were made ...

Problems solved by technology

When one wakes up, hay fever is at its most tormenting, and in the morning hours, as ones blood pressure rises to meet the day, one is most likely to suffer a heart attack or stroke.
Rheumatoid arthritis improves through the day, but osteoarthritis grows worse.
This disintegration would typically have a detrimental effect upon the su...

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Examples

Experimental program
Comparison scheme
Effect test

example 2

[0178] A delayed release material to be used in the compression coatings of the invention is prepared having the following formulation listed in Table 2:

2TABLE 2 Component Percentage 1. Xanthan Gum 25 2. Locust Bean Gum 25 3. Dextrose 35 4. Calcium Sulfate Dihydrate 10 5. Ethylcellulose 5 5. Alcohol, SD3A, anhydrous* 20 6. Water* q.s. *Removed during processing

[0179] Process:

[0180] 1. The requisite amounts of xanthan gum, locust bean gum, calcium sulfate, and dextrose are dry blended in a high speed mixer / granulator for 3 minutes.

[0181] 2. A slurry of hydrophobic polymer (ethylcellulose) is prepared by dissolving ethyl cellulose in ethyl alcohol.

[0182] 3. The slurry is added to the dry blended mixture, and granulated for another 3 minutes.

[0183] 4. The granulation was then dried in a fluid bed dryer to a LOD (loss on drying) of less than about 10% by weight (e.g., 4-7% LOD).

example 3

[0184] A delayed release material to be used in the compression coatings of the invention is prepared having the following formulation listed in Table 3:

3TABLE 3 Component Percentage 1. Xanthan Gum 15 2. Locust Bean Gum 15 3. Dextrose 60 4. Calcium Sulfate Dihydrate 10 5. Water* q.s. *Removed during processing

[0185] Process:

[0186] 1. The requisite amounts of xanthan gum, locust bean gum, calcium sulfate, and dextrose are dry blended in a high speed mixer / granulator for 3 minutes.

[0187] 2. Water (125-150 ml) is added to the dry blended mixture, and granulated for another 3 minutes.

[0188] 3. The granulation is then dried in a fluid bed dryer to a LOD (loss on drying) of less than about 10% by weight (e.g., 4-7% LOD).

example 4

[0189] A delayed release material to be used in the compression coatings of the invention is prepared having the following formulation listed in Table 4:

4TABLE 4 Component Percentage 1. Xanthan Gum 16 2. Locust Bean Gum 24 3. Dextrose 60 4. Water* q.s. *Removed during processing

[0190] Process:

[0191] The same process for Example 1 is used to prepare the delayed release coating of Example 4.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

PropertyMeasurementUnit
Weightaaaaaaaaaa
Weightaaaaaaaaaa
Fractionaaaaaaaaaa
Login to view more

Abstract

A chronotherapeutic pharmaceutical formulation comprising a core containing an active agent (e.g., a drug) and a delayed release compression coating comprising a natural or synthetic gum applied onto the surface of the core.

Description

[0001] This application claims priority from U.S. Provisional Application No. 60 / 275,382, filed Mar. 31, 2001, the disclosure of which is hereby incorporated by reference in its entirety.[0002] The present invention relates to a chronotherapeutic dosage form containing a therapeutically effective amount of a drug. The present invention is further related to methods of preparing such formulations, and to methods of treatment utilizing such formulations.[0003] Coordinating biological rhythms (chronobiology) with medical treatment is called chronotherapy. Chronotherapy takes into consideration a person's biological rhythms in determining the timing--and sometimes the amount--of medication to optimize desired effects of a drug(s) and minimize the undesired effects. The synchronization of medication levels to the biological rhythms of disease activity is playing an increasing role in the management of common cardiovascular conditions such as hypertension, elevated cholesterol, angina, st...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
IPC IPC(8): A61K9/20A61J3/06A61K9/22A61K9/26A61K9/28A61K9/30A61K9/32A61K9/34A61K9/36A61K31/573A61K47/02A61K47/04A61K47/10A61K47/12A61K47/26A61K47/30A61K47/32A61K47/36A61K47/38A61K47/44A61K47/46A61M37/00A61P5/00A61P9/10A61P9/12A61P11/08A61P19/02
CPCA61K9/2009A61K9/2054A61K9/2813A61K31/573A61K9/286A61K9/2866A61K9/2826A61P11/08A61P19/02A61P5/00A61P9/10A61P9/12A61K9/20
Inventor BAICHWAL, ANAND R.WOODCOCK, PAULHIGGINS, RAYMONDCOBB, JACLYN
Owner PENWEST PHARMA CO
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products